Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cellular Biomedicine Group Inc (NASDAQ:CBMG)

10.80
Delayed Data
As of Apr 28
 +0.10 / +0.93%
Today’s Change
10.05
Today|||52-Week Range
17.94
-17.56%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$154.2M

Company Description

Cellular Biomedicine Group, Inc. is a biopharmaceutical company. The company engages in the development of treatments for degenerative and cancerous diseases utilizing proprietary cell-based technologies. Its technology include immune cell therapy for treatment of a range of cancers using Chimeric Antigen Receptor T cell, cancer vaccine, and T Central Memory cell technology; and human adipose-derived mesenchymal progenitor cells for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. Cellular Biomedicine Group was founded in 2009 and is headquartered in Cupertino, CA.

Contact Information

Cellular Biomedicine Group, Inc.
19925 Stevens Creek Boulevard
Cupertino California 94301
P:(408) 973-7884
Investor Relations:
(650) 566-5064

Employees

Shareholders

Mutual fund holders5.54%
Other institutional4.67%
Individual stakeholders28.95%

Top Executives

Bizuo LiuDirector, Chief Executive & Financial Officer
Maxwell WangDirector-Medical Research
Cheng Xiang DaiSenior Vice President-Clinical Development
Yihong YaoChief Scientific Officer
Li ZhangVice President-Technology & Manufacturing